Company intelligence / Profile preview

Huixin LifeTech

Shenzhen, Guangdong, Chinatracxn.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company develops automated exosome purification systems aimed at early cancer diagnosis and potentially treatment. No active clinical trials are registered for therapeutics as of June 2025. Their technology focuses on improving the standardization and recovery rate of exosomes from biological samples. Products include a non-labeled automatic purification system for exosome separation and purification. No active trials found on ClinicalTrials.gov.

Therapeutic areas: Oncology
Modalities: DeviceExosome-based therapy (potentially in development)Diagnostic platform (exosome purification/diagnostics)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Huixin LifeTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huixin LifeTech.

Explore the full profile